Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease
| Autor: | Patrick T F Kennedy, G E Dolman |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Hepatitis B virus HBsAg biology business.industry medicine.medical_treatment Gastroenterology virus diseases Immunosuppression Hepatitis B medicine.disease medicine.disease_cause Inflammatory bowel disease digestive system diseases Virus 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Antigen Immunology medicine biology.protein 030211 gastroenterology & hepatology Antibody business |
| Zdroj: | Gut. 69:2053-2054 |
| ISSN: | 1468-3288 0017-5749 |
| DOI: | 10.1136/gutjnl-2019-319480 |
| Popis: | We would like to congratulate Lamb et al for the production of such a comprehensive guideline for the management of inflammatory bowel disease (IBD).1 Further clarification is warranted regarding screening for hepatitis B virus (HBV) prior to immunosuppression and subsequent management to reduce the risk of virus reactivation. The guidelines recommend screening for HBV at diagnosis and before immunomodulatory/biologic therapies. We strongly recommend that screening includes hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc) and antibody to hepatitis B surface antigen (anti-HBs) as outlined in the European Crohn’s and Colitis Organisation Opportunistic Infections Consensus.2 Lamb et al advise seeking specialist input prior to commencing immune-modifying therapy for those patients with active HBV (i.e. HBsAg positive). In line with national and international guidelines, … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|